Patients' adherence to secondary prevention pharmacotherapy after acute coronary syndromes

被引：0
|
作者：
Kassab, Y. W. [1 ]
AbdulRazzaq, H. A. [1 ]
Altaie, A. H. [2 ]
Hassan, Y. [3 ]
Abd Aziz, N. [3 ]
Najjar, M. F. [4 ]
Ismail, O. [5 ]
机构：
[1] Univ Sci Malaysia, Sch Pharmaceut Sci, George Town, Malaysia
[2] Ankara Univ, Tomer Inst, TR-06100 Ankara, Turkey
[3] Univ Teknol MARA, Fac Pharm, Kuala Lumpur, Malaysia
[4] King Abdullah Int Med Res Ctr, Dept Clin Pharm, Riyadh, Saudi Arabia
[5] Hosp Pulau Pinang, Dept Cardiol, George Town, Malaysia
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2013年 / 35卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：911 / 911
页数：1
相关论文
共 50 条
  • [41] Adherence to secondary prevention measures after acute coronary syndrome in patients associated exclusively with the public and private healthcare systems in Brazil
    Costa, Ingrid Maria Novais Barros de Carvalho
    Silva, Danielle Goes da
    Oliveira, Joselina Luzia Meneses
    Silva, Jose Rodrigo Santos
    Pereira, Larissa Monteiro Costa
    Alves, Luciana Vieira Sousa
    Andrade, Fabricio Anjos de
    Jorge, Juliana de Goes
    Oliveira, Larissa Marina Santana Mendonca de
    Almeida, Rebeca Rocha de
    Oliveira, Victor Batista
    Martins, Larissa Santos
    Costa, Jamille Oliveira
    Souza, Marcia Ferreira Candido de
    Voci, Silvia Maria
    Almeida-Santos, Marcos Antonio
    Abreu, Victoria Vieira
    Aidar, Felipe J.
    Baumworcel, Leonardo
    Sousa, Antonio Carlos Sobral
    PREVENTIVE MEDICINE REPORTS, 2022, 29
  • [42] Secondary prevention medications in diabetic patients after an acute coronary syndrome.
    Gourdy, P
    Ferrières, J
    Cambou, JP
    Grenier, O
    Danchin, N
    Hanaire-Broutin, H
    DIABETOLOGIA, 2001, 44 : A303 - A303
  • [43] Apixaban for prevention of acute ischemic events in patients with acute coronary syndromes
    James, S. K.
    Alexander, J. H.
    Mohan, P.
    Wallentin, L.
    Harrington, R. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 20 - 20
  • [44] Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery
    Huynh, T
    Théroux, P
    Bogaty, P
    Nasmith, J
    Solymoss, S
    CIRCULATION, 2001, 103 (25) : 3069 - 3074
  • [45] Adherence to Cardio-protective Medications Prescribed for Secondary Prevention After Hospitalization for an Acute Coronary Syndrome
    Rana, Jamal S.
    Parker, Melissa M.
    Moffet, Howard H.
    Karter, Andrew J.
    CIRCULATION, 2017, 136
  • [46] Failure of secondary prevention after acute coronary syndrome
    Bouamaied, N.
    Monassier, J. P.
    DIABETES & METABOLISM, 2007, 33 : S83 - S83
  • [47] Contemporary Antiplatelet Pharmacotherapy in the Management of Acute Coronary Syndromes
    Mangels D.R.
    Nathan A.
    Tuteja S.
    Giri J.
    Kobayashi T.
    Current Treatment Options in Cardiovascular Medicine, 2018, 20 (2)
  • [48] One-year persistence and adherence rates to secondary prevention drugs prescribed in-hospital in patients with acute coronary syndromes. The ALASCA Study
    Bueno, H.
    Bardaji, A.
    Castillo, J. A.
    Carreno, A.
    Merino, S.
    Barrabes, J.
    EUROPEAN HEART JOURNAL, 2010, 31 : 375 - 376
  • [49] Sex disparity in secondary prevention pharmacotherapy and clinical outcomes following acute coronary syndrome
    Dagan, Misha
    Dinh, Diem T.
    Stehli, Julia
    Tan, Christianne
    Brennan, Angela
    Warren, Josephine
    Ajani, Andrew E.
    Freeman, Melanie
    Murphy, Alexandra
    Reid, Christopher M.
    Hiew, Chin
    Oqueli, Ernesto
    Clark, David J.
    Duffy, Stephen J.
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2022, 8 (04) : 420 - 428
  • [50] Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome
    Thompson, Peter L.
    Thompson, Angus G.
    Judkins, Chris
    MEDICAL JOURNAL OF AUSTRALIA, 2014, 201 (10) : S100 - S105
12345